<DOC>
	<DOCNO>NCT03023319</DOCNO>
	<brief_summary>This study determine maximum-tolerated dose ( MTD ) oral bosutinib use combination pemetrexed . The MTD high dose bosutinib pemetrexed give without cause severe side effect . This study also test safety combination see effect ( good bad ) participant cancer .</brief_summary>
	<brief_title>Bosutinib Combination With Pemetrexed Patients With Selected Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologically cytologically proven advanced , metastatic nonsquamous nonsmall cell lung cancer , pleural malignant mesothelioma , bladder urethral cancer , ovarian cancer , primary peritoneal cancer , thymoma thymic cancer uterine cervical cancer . Measurable disease Life expectancy great 3 month . Ability take folic acid , vitamin B12 , dexamethasone accord protocol . Untreated symptomatic brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>